Introduction
Methods
Study subjects
Clinical variables
Definitions
Statistical analysis
Results
Comparison of baseline demographic, clinical, and laboratory characteristics between the antibiotic and no-antibiotic groups
Total (n = 1134) | Antibiotics (n = 681) | None (n = 453) | P value | |
---|---|---|---|---|
Age,years | 50.1 ± 16.2 | 50.5 ± 16.4 | 49.5 ± 16.0 | 0.247 |
Male,n(%) | 747(65.8) | 447(65.6) | 300(66.2) | 0.445 |
BMI Index (kg/m2) | 25.6 ± 4.3 | 25.6 ± 4.4 | 25.2 ± 4.1 | 0.548 |
Etiology | ||||
Biliary,n(%) | 654(57.6) | 388(59.3) | 266(40.7) | 0.560 |
Hyperlipidemic,n(%) | 353(31.1) | 211(59.8) | 142(40.2) | 0.897 |
Alcoholic,n(%) | 71(6.2) | 37(52.1) | 34(47.9) | 0.158 |
Other,n(%) | 56(4.9) | 45(52.1) | 11(19.6) | 0.200 |
Severity Grade | ||||
Mild,n(%) | 459(40.4) | 132(19.3) | 327(72.1) | < 0.001* |
Moderate-severe,n(%) | 429(37.8) | 322(47.2) | 107(23.6) | < 0.001* |
Severe,n(%) | 246(21.6) | 227(33.3) | 19(2.4) | < 0.001* |
Comorbidity | ||||
HBP,n(%) | 383(33.7) | 230(60.1) | 153(39.9) | 0.492 |
DM,n(%) | 224(19.7) | 148(66.1) | 76(33.9) | 0.023* |
Smoking,n(%) | 355(31.2) | 229(33.6) | 126(66.4) | 0.220 |
Drinking,n(%) | 352(31.0) | 216(61.4) | 136(38.6) | 0.295 |
Laboratory indicators on admission | ||||
Leukocyte count(×109/L) | 14.2 ± 5.3 | 14.7 ± 5.3 | 13.3 ± 5.1 | 0.338 |
Pct(ng/ml) | 3.6 ± 9.2 | 4.7 ± 10.8 | 1.1 ± 2.6 | < 0.001* |
CRP(μg/ml) | 140.0 ± 117.9 | 144.2 ± 125.2 | 89.4 ± 102.4 | < 0.001* |
Platelet count(×109/L) | 204.0 ± 67.3 | 206.9 ± 65.3 | 203.9 ± 68.8 | 0.560 |
Serum amylase(U/L) | 866.0 ± 1158.0 | 954.6 ± 1316.8 | 693.0 ± 827.3 | 0.003* |
Alanine aminotransferase(U/L) | 71.7 ± 110.0 | 73.4 ± 114.0 | 69.3 ± 106.0 | 0.341 |
Total bilirubin(μmol/L) | 29.0 ± 32.3 | 30.4 ± 36.8 | 26.8 ± 24.1 | 0.021* |
Creatinine(μmol/L) | 85.1 ± 67.0 | 92.7 ± 79.2 | 73.4 ± 40.0 | < 0.001* |
Calcium(mmol/L) | 2.1 ± 5.2 | 2.2 ± 6.8 | 2.0 ± 0.1 | 0.203 |
Glucose(mmol/L) | 9.3 ± 4.7 | 9.1 ± 4.8 | 9.1 ± 4.8 | 0.945 |
Potassium(mmol/L) | 3.8 ± 0.6 | 3.9 ± 0.6 | 3.8 ± 0.5 | 0.469 |
Triglycerides(mmol/L) | 7.2 ± 13.4 | 8.3 ± 15.3 | 5.4 ± 9.3 | < 0.001* |
Modified Marshall score | 0(0–8) | 0(0–6) | 0(0–8) | 0.469 |
BISAP score | 1(0–6) | 2(0–5) | 0(0–4) | < 0.001* |
APACHE II score | 5(0–29) | 7(0–29) | 5(0–29) | 0.348 |
CTSI score | 4(0–8) | 4(0–8) | 3(0–8) | < 0.001* |
Laparotomy,n(%) | 47(4.1) | 36(5.3) | 11(2.4) | 0.012* |
Length of hospital stay,(days) | 24.8 ± 23.5 | 28.9 ± 24.5 | 29.4 ± 26.1 | 0.753 |
In-hospital mortality,n(%) | 34(2.99) | 28(4.1) | 6(1.3) | 0.735 |
Comparison of baseline demographic, clinical, and laboratory characteristics between antibiotic and no antibiotic groups in AP of different etiologies and disease severity
Total | Antibiotics | None | P value | ||
---|---|---|---|---|---|
Biliary pancreatitis | n = 650 | n = 386 | n = 264 | ||
Age,years | 56.1 ± 16.4 | 57.3 ± 16.1 | 54.2 ± 16.7 | 0.835 | |
Male,n(%) | 392(59.9) | 149(38.0) | 113(42.4) | 0.296 | |
BMI Index (kg/m2) | 24.7 ± 4.1 | 24.9 ± 4.1 | 24.4 ± 4.0 | 0.733 | |
Smoking,n(%) | 153(23.3) | 98(25.0) | 55(20.6) | 0.621 | |
Drinking,n(%) | 139(21.2) | 89(22.9) | 50(18.7) | 0.984 | |
Comorbidity | |||||
HBP,n(%) | 234(35.7) | 142(36.5) | 92(34.5) | 0.120 | |
DM,n(%) | 83(12.6) | 55(14.1) | 28(7.2) | 0.982 | |
Severity Grade | |||||
Mild,n(%) | 273(41.7) | 69(25.2) | 204(74.7) | < 0.001* | |
Moderate-severe,n(%) | 263(40.2) | 212(80.6) | 51(19.3) | < 0.001* | |
Severe,n(%) | 118(18.0) | 11(9.3) | 107(90.6) | < 0.001* | |
Laboratory indicators on admission | |||||
Leukocyte count(×109/L) | 14.3 ± 5.6 | 15.9 ± 5.7 | 13.1 ± 4.1 | 0.325 | |
Pct(ng/ml) | 2.9 ± 6.8 | 3.8 ± 7.9 | 1.2 ± 3.2 | < 0.001* | |
CRP(μg/ml) | 105.0 ± 98.0 | 120.4 ± 103.9 | 79.5 ± 81.6 | < 0.001* | |
Platelet count(× 109/L) | 200.8 ± 67.5 | 120.4 ± 103.9 | 203.5 ± 64.8 | 0.840 | |
Serum amylase(U/L) | 1096.1 ± 1069.8 | 1229.0 ± 1132.4 | 902.5 ± 940.4 | 0.039* | |
Alanine aminotransferase(U/L) | 100.0 ± 130.3 | 107.7 ± 133.4 | 88.9 ± 125.2 | 0.142 | |
Total bilirubin(μmol/L) | 33.5 ± 34.5 | 35.3 ± 38.0 | 30.9 ± 28.5 | 0.100 | |
Creatinine(μmol/L) | 85.4 ± 62.3 | 93.0 ± 73.2 | 74.2 ± 39.1 | < 0.001* | |
Calcium(mmol/L) | 2.0 ± 0.2 | 2.0 ± 0.2 | 2.0 ± 0.1 | < 0.001* | |
Glucose(mmol/L) | 8.3 ± 4.1 | 8.5 ± 4.2 | 7.9 ± 3.8 | 0.527 | |
Potassium(mmol/L) | 3.8 ± 0.5 | 3.8 ± 0.5 | 3.5 ± 3.8 | 0.735 | |
Triglycerides(mmol/L) | 1.7 ± 2.0 | 1.7 ± 2.0 | 1.8 ± 2.0 | 0.998 | |
Modified Marshall score | 0(0–8) | 0(0–6) | 0(0–8) | 0.957 | |
BISAP score | 1(0–6) | 2(0–6) | 1(0–4) | 0.069 | |
APACHE II score | 5(0–29) | 6(0–29) | 3(0–27) | 0.990 | |
CTSI score | 4(0–8) | 4(0–8) | 3(0–8) | < 0.001* | |
Laparotomy,(n%) | 30(4.5) | 22(5.6) | 8(2.0) | 0.104 | |
Length of hospital stay,(days) | 23.2 ± 23.7 | 25.4 ± 24.9 | 19.9 ± 21.5 | 0.130 | |
In-hospital mortality,n(%) | 21(3.2) | 15(3.8) | 6(2.2) | 0.105 | |
Hyperlipidemic pancreatitis | n = 352 | n = 211 | n = 141 | ||
Age,years | 40.6 ± 11.0 | 39.9 ± 10.8 | 41.7 ± 11.3 | 0.418 | |
Male,n(%) | 100(28.3) | 67(31.7) | 33(23.2) | 0.296 | |
BMI Index (kg/m2) | 26.5 ± 4.1 | 27.3 ± 4.8 | 26.5 ± 4.3 | 0.204 | |
Smoking,n(%) | 140(39.6) | 85(40.2) | 55(38.0) | 0.087 | |
Drinking,n(%) | 131(37.1) | 72(34.1) | 59(41.5) | 0.675 | |
Comorbidity | |||||
HBP, n(%) | 106(30.0) | 61(28.9) | 44(30.9) | 0.309 | |
DM, n(%) | 112(31.7) | 72(34.1) | 40(28.1) | 0.767 | |
Severity Grade | |||||
Mild, n(%) | 139(39.3) | 48(22.7) | 91(64.0) | < 0.001* | |
Moderate-severe,n(%) | 124(35.1) | 78(26.9) | 46(32.3) | 0.378 | |
Severe,n(%) | 90(25.4) | 85(40.2) | 5(3.5) | < 0.001* | |
Laboratory indicators on admission | |||||
Leukocyte count(×109/L) | 14.1 ± 4.7 | 14.2 ± 4.6 | 13.9 ± 4.8 | 0.110 | |
Pct(ng/ml) | 3.9 ± 11.0 | 5.6 ± 13.4 | 0.8 ± 1.2 | 0.086 | |
CRP(μg/ml) | 185.0 ± 123.3 | 206.1 ± 125.3 | 152.3 ± 112.9 | 0.586 | |
Platelet count(×109/L) | 213.5 ± 67.7 | 215.0 ± 69.4 | 211.3 ± 65.2 | 0.355 | |
Serum amylase(U/L) | 521.0 ± 1344.0 | 621.0 ± 1694.4 | 377.4 ± 501.9 | 0.550 | |
Alanine aminotransferase(U/L) | 26.9 ± 23.1 | 25.3 ± 17.4 | 29.4 ± 29.6 | 0.162 | |
Total bilirubin(μmol/L) | 21.8 ± 29.2 | 22.9 ± 36.3 | 20.1 ± 12.3 | 0.391 | |
Creatinine(μmol/L) | 81.7 ± 57.3 | 88.9 ± 77.9 | 70.9 ± 45.6 | 0.125 | |
Calcium(mmol/L) | 2.4 ± 9.4 | 2.7 ± 12.2 | 2.1 ± 0.2 | 0.365 | |
Glucose(mmol/L) | 10.9 ± 5.1 | 12.1 ± 5.4 | 9.2 ± 3.9 | 0.039* | |
Potassium(mmol/L) | 3.9 ± 0.6 | 3.9 ± 0.7 | 3.9 ± 0.5 | 0.119 | |
Triglycerides(mmol/L) | 19.3 ± 97.1 | 17.0 ± 21.3 | 10.0 ± 12.8 | 0.864 | |
Modified Marshall score | 0(0–6) | 0(0–6) | 0(0–2) | 0.043* | |
BISAP score | 1(0–4) | 1(0–4) | 0(0–3) | 0.269 | |
APACHE II score | 6(0–25) | 8(0–25) | 2(0–17) | 0.536 | |
CTSI score | 4(1–8) | 5(2–8) | 3(1–8) | 0.524 | |
Laparotomy, n(%) | 8(2.26) | 7(3.3) | 1(0.7) | 0.999 | |
Length of hospital stay,(days) | 26.2 ± 19.9 | 33.1 ± 20.9 | 15.9 ± 12.7 | 0.130 | |
In-hospital mortality, n(%) | 6(1.6) | 6(2.8) | 0(0) | 0.999 | |
Alcoholic pancreatitis | n = 71 | n = 37 | n = 34 | ||
Age,years | 46.7 ± 11.8 | 46.6 ± 10.9 | 46.8 ± 12.9 | 0.997 | |
Male,n(%) | 10(14.0) | 5(13.5) | 5(14.7) | 0.999 | |
BMI Index(kg/m2) | 26.2 ± 3.7 | 26.5 ± 4.1 | 25.8 ± 3.4 | 0.995 | |
Smoking,n(%) | 39(54.9) | 25(67.5) | 14(41.1) | 1 | |
Drinking,n(%) | 71(100) | 37(100) | 34(100) | 0.999 | |
Comorbidity | |||||
HBP,n(%) | 12(39.4) | 12(32.4) | 16(47.0) | 0.999 | |
DM,n(%) | 8(21.1) | 8(21.6) | 7(20.5) | 0.995 | |
Laboratory indicators on admission | |||||
Leukocyte count(×109/L) | 13.7 ± 4.9 | 14.2 ± 4.7 | 13.1 ± 5.2 | 0.993 | |
Pct(ng/ml) | 4.1 ± 10.7 | 5.4 ± 13.4 | 2.0 ± 3.4 | 0.999 | |
CRP(μg/ml) | 130.7 ± 128.7 | 140.4 ± 129.7 | 120.0 ± 129.0 | 0.999 | |
Platelet count(× 109/L) | 206.1 ± 67.7 | 203.8 ± 62.9 | 208.6 ± 73.6 | 0.996 | |
Serum amylase(U/L) | 697.1 ± 781.6 | 837.1 ± 916.6 | 548.7 ± 585.0 | 0.999 | |
Alanine aminotransferase(U/L) | 46.6 ± 86.5 | 41.5 ± 97.2 | 52.2 ± 74.2 | 0.997 | |
Total bilirubin(μmol/L) | 23.1 ± 15.0 | 21.0 ± 7.9 | 25.4 ± 20.0 | 0.995 | |
Creatinine(μmol/L) | 97.1 ± 100.7 | 113.1 ± 137.2 | 79.7 ± 20.1 | 1 | |
Calcium(mmol/L) | 2.0 ± 0.2 | 1.9 ± 0.3 | 2.0 ± 0.1 | 0.994 | |
Glucose(mmol/L) | 9.0 ± 5.6 | 10.4 ± 6.9 | 7.6 ± 3.3 | 0.999 | |
Potassium(mmol/L) | 3.9 ± 0.5 | 3.8 ± 0.5 | 3.7 ± 0.4 | 0.998 | |
Triglycerides(mmol/L) | 3.5 ± 4.9 | 2.8 ± 3.1 | 4.3 ± 6.4 | 0.994 | |
Modified Marshall score | 0(0–6) | 0(0–6) | 0(0–3) | 0.957 | |
BISAP score | 1(0–4) | 1(0–4) | 1(0–4) | 0.069 | |
APACHE II score | 3(0–18) | 6(0–18) | 2(0–16) | 0.990 | |
CTSI score | 4(1–8) | 4(1–8) | 3(1–6) | 0.997 | |
Laparotomy, n(%) | 10(14.0) | 2(5.4) | 8(0) | 1 | |
Length of hospital stay,(days) | 25.7 ± 29.4 | 34.8 ± 36.7 | 15.7 ± 13.0 | 0.993 | |
In-hospital mortality,n(%) | 4(5.6) | 4(21.6) | 0(0) | 1 | |
Other | n = 56 | n = 45 | n = 11 | ||
Age,years | 44.48 ± 15.36 | 44.73 ± 14.88 | 43.45 ± 17.93 | 0.835 | |
Male,n(%) | 15(26.78) | 13(28.8) | 2(18.1) | 0.296 | |
BMI Index(kg/m2) | 26.42 ± 3.91 | 26.73 ± 3.93 | 25.13 ± 3.73 | 0.820 | |
Smoking,n(%) | 22(39.28) | 20(62.5) | 2(18.1) | 0.621 | |
Drinking,n(%) | 25(44.64) | 23(71.8) | 2(18.1) | 0.984 | |
Comorbidity | |||||
HBP,n(%) | 12(18.46) | 11(34.3) | 1(9) | 0.120 | |
DM,n(%) | 8(14.28) | 7(21.8) | 1(9) | 0.982 | |
Laboratory indicators on admission | |||||
Leukocyte count(×109/L) | 13.74 ± 5.64 | 13.72 ± 5.87 | 13.83 ± 4.84 | 0.947 | |
Pct(ng/ml) | 5.00 ± 9.01 | 5.61 ± 9.46 | 0.64 ± 0.82 | 0.064 | |
CRP(μg/ml) | 217.12 ± 124.12 | 234.73 ± 123.09 | 79.58 ± 81.65 | 0.186 | |
Platelet count(×109/L) | 194.50 ± 57.24 | 195.04 ± 58.86 | 192.27 ± 52.63 | 0.484 | |
Serum amylase(U/L) | 532.22 ± 505.39 | 542.38 ± 515.03 | 486.5 ± 482.58 | 0.754 | |
Alanine aminotransferase(U/L) | 54.13 ± 121.23 | 60.07 ± 134.5 | 29.82 ± 20.57 | 0.171 | |
Total bilirubin(μmol/L) | 29.04 ± 32.58 | 31.43 ± 35.84 | 19.25 ± 7.39 | 0.117 | |
Creatinine(μmol/L) | 87.84 ± 64.09 | 91.38 ± 70.41 | 73.36 ± 22.04 | 0.097 | |
Calcium(mmol/L) | 1.86 ± 0.38 | 1.81 ± 0.28 | 2.06 ± 0.35 | 0.881 | |
Glucose(mmol/L) | 11.07 ± 4.44 | 11.68 ± 4.33 | 8.62 ± 4.23 | 0.932 | |
Potassium(mmol/L) | 3.97 ± 0.64 | 3.99 ± 0.67 | 3.91 ± 0.57 | 0.938 | |
Triglycerides(mmol/L) | 11.99 ± 11.72 | 13.47 ± 12.31 | 6.06 ± 6.47 | 0.079 | |
Modified Marshall score | 1(0–4) | 0(0–6) | 0(0–8) | 0.196 | |
BISAP score | 2(0–4) | 2(0–6) | 1(0–4) | 0.218 | |
APACHE II score | 8(1–29) | 6(0–29) | 3(0–27) | 0.149 | |
CTSI score | 6(1–8) | 4(0–8) | 3(0–8) | 0.849 | |
Laparotomy, n(%) | 3(4.6) | 3(9.3) | 0(0) | 0.104 | |
Length of hospital stay,(days) | 34.75 ± 30.34 | 25.46 ± 24.98 | 19.97 ± 21.51 | 0.574 | |
In-hospital mortality,n(%) | 3(5.35) | 3(9.3)0 | 0(0) | 0.105 |
Comparison of clinical prognosis between antibiotic and no antibiotic groups in AP of different etiology and disease severity
Biliary AP
Antibiotics | None | P value | |||
---|---|---|---|---|---|
Biliary Pancreatitis | |||||
SAP | n = 105 | n = 11 | |||
Laparotomy, n(%) | 22(20.9) | 8(72.7) | < 0.001* | ||
Length of hospital stay, days | 50.3 ± 33.6 | 91.0 ± 49.4 | 0.024* | ||
In-hospital mortality,n(%) | 12(11.4) | 2(18.2) | 0.621 | ||
AKI, n(%) | 47(44.7) | 6(54.5) | 0.546 | ||
CRRT,n(%) | 10(9.5) | 3(27.3) | 0.107 | ||
MV,n(%) | 52(49.5) | 10(90.9) | 0.010* | ||
MSAP | n = 212 | n = 51 | |||
Length of hospital stay, days | 18.2 ± 10.9 | 91.0 ± 49.4 | 0.001* | ||
In-hospital mortality,n(%) | 0(0) | 2(3.9) | 0.037* | ||
AKI, n(%) | 13(6.1) | 3(5.5) | 0.947 | ||
MAP | n = 69 | n = 204 | |||
Length of hospital stay, days | 9.07 ± 3.8 | 12.25 ± 5.0 | 0.060 | ||
Hyperlipidemic pancreatitis | |||||
SAP | n = 85 | n = 5 | |||
Laparotomy, n(%) | 7(8.2) | 1(20) | 0.369 | ||
Length of hospital stay, days | 44.4 ± 24.0 | 54.0 ± 39.1 | 0.075 | ||
In-hospital mortality,n(%) | 6(7.1) | 0 | 1 | ||
AKI, n(%) | 35(41.2) | 0 | 0.152 | ||
CRRT,n(%) | 15(17.6) | 0 | 0.588 | ||
MV,n(%) | 40(47.1) | 3(60.0) | 0.667 | ||
MSAP | n = 78 | n = 46 | |||
Length of hospital stay, days | 30.2 ± 14.7 | 21.3 ± 9.9 | 0.064 | ||
In-hospital mortality,n(%) | 1(1.2) | 0 | 1 | ||
AKI, n(%) | 4(5.1) | 3(6.5) | 0.710 | ||
MAP | n = 48 | n = 90 | |||
Length of hospital stay, days | 17.9 ± 9.9 | 16.9 ± 8.3 | 0.921 | ||
Alcoholic Pancreatitis | |||||
SAP | n = 13 | n = 2 | |||
Laparotomy, n(%) | 2(15.3) | 0(0) | 1 | ||
Length of hospital stay, days | 54.4 ± 56.1 | 52.5 ± 26.1 | 0.516 | ||
In-hospital mortality,n(%) | 3(23.1) | 0(0) | 1 | ||
AKI, n(%) | 3(23.1) | 2(100) | 0.095 | ||
CRRT,n(%) | 2(15.3) | 0(0) | 1 | ||
MV,n(%) | 10(66.7) | 1(50) | 0.476 | ||
MSAP | n = 15 | n = 10 | |||
Length of hospital stay, days | 27.4 ± 12.4 | 21.6 ± 9.1 | 0.233 | ||
In-hospital mortality,n(%) | 1(6.6) | 0 | 1 | ||
AKI, n(%) | 1(6.6) | 0 | 1 | ||
MAP | n = 9 | n = 22 | |||
Length of hospital stay, days | 19.0 ± 9.4 | 9.8 ± 4.1 | 0.034* | ||
Other | |||||
SAP | n = 22 | n = 1 | |||
Laparotomy, n(%) | 2 (15.3) | 0(0) | 1 | ||
Length of hospital stay, days | 54.4 ± 56.1 | – | 0.516 | ||
In-hospital mortality,n(%) | 3 (23.1) | 0(0) | 1 | ||
AKI, n(%) | 3(23.1) | 2(100) | 0.095 | ||
CRRT,n(%) | 2(15.3) | 0(0.0) | 1 | ||
MV,n(%) | 10(66.7) | 1(50) | 0.476 | ||
MSAP | n = 17 | n = 0 | |||
Length of hospital stay,days | 27.4 ± 12.4 | 21.6 ± 9.1 | 0.233 | ||
In-hospital mortality,n(%) | 1(6.6) | 0 | 1 | ||
AKI, n(%) | 1(6.6) | 0 | 1 | ||
MAP | n = 6 | n = 10 | |||
Length of hospital stay,days | 15.8 ± 7.8 | 12.0 ± 5.3 | 0.317 |
Hyperlipidemic AP
Alcoholic AP
Other types of AP
Comparison of clinical prognosis of different antibiotic use strategies in AP of different etiology and disease severity
Biliary AP
Antibiotics | None | |||||
---|---|---|---|---|---|---|
Carbapenem | Third generation cephalosporin | Quinolones | ||||
Biliary Pancreatitis | ||||||
SAP | n = 88 | n = 17 | n = 11 | |||
Laparotomy,(%) | 16(18.2) | 5(31.6) | 8(72.7)*▴ | |||
Length of hospital stay, days | 45.8 ± 29.5 | 71.1 ± 45.5# | 91.0 ± 49.4* | |||
In-hospital mortality,(%) | 9 (10.2) | 5 (26.3)# | 2(18.2) | |||
AKI,n(%) | 39(44.3) | 8(42.1) | 6(54.5) | |||
CRRT,n(%) | 9(10.2) | 1(5.3) | 3(27.3) | |||
MV,n(%) | 41(46.6) | 11(57.9) | 10(90.9)* | |||
MSAP | n = 10 | n = 187 | n = 15 | n = 51 | ||
Length of hospital stay, days | 32.6 ± 14.6 | 17.8 ± 10.9 | 14.2 ± 5.9 | 36.6 ± 18.4*▴▪ | ||
In-hospital mortality,(%) | 0 | 1(0.5) | 0 | 2(3.9)▴ | ||
AKI,n(%) | 1(10.0) | 11(5.9) | 1(0.5) | 5(9.8) | ||
MAP | n = 2 | n = 50 | n = 17 | n = 204 | ||
Length of hospital stay, days | 7.0 ± 1.4 | 9.3 ± 4.0 | 8.5 ± 3.2 | 12.2 ± 5.0▪ | ||
Hyperlipidemic pancreatitis | SAP | n = 20 | n = 65 | n = 5 | ||
Laparotomy,(%) | 3 (15.0) | 4 (6.2) | 1(20.0) | |||
Length of hospital stay, days | 47.1 ± 25.2 | 43.5 ± 23.8 | 54.0 ± 39.1 | |||
In-hospital mortality,(%) | 1(5.0) | 5(7.7) | 0 | |||
AKI, n(%) | 11(55.0) | 24(36.9) | 0* | |||
CRRT,n(%) | 15(17.6) | 10(15.4) | 0 | |||
MV,n(%) | 41(46.6) | 11(57.9) | 10(90.9)* | |||
MSAP | n = 7 | n = 66 | n = 5 | n = 46 | ||
Length of hospital stay, days | 41.6 ± 21.0 | 30.1 ± 15.3 | 25.8 ± 10.0 | 21.3 ± 9.9▴ | ||
In-hospital mortality,(%) | 0 | 1(1.4) | 0 | 0 | ||
AKI, n(%) | 1(14.3) | 3(4.5) | 0 | 3(6.5) | ||
MAP | n = 1 | n = 42 | n = 5 | n = 90 | ||
Length of hospital stay, days | – | 8.5 ± 3.2 | 14.0 ± 4.1 | 11.1 ± 4.4 | ||
Alcoholic pancreatitis | SAP | n = 9 | n = 4 | n = 2 | ||
Laparotomy,(%) | 2(22.2) | 0 | 0(0) | |||
Length of hospital stay, days | 65.6 ± 65.1 | 29.2 ± 10.9 | 52.5 ± 26.1▴ | |||
In-hospital mortality,(%) | 3(33.3) | 0 | 0(0) | |||
AKI, n(%) | 4(44.4) | 1(25.0) | 2(100) | |||
CRRT,n(%) | 2(22.2) | 0 | 0(0) | |||
MV,n(%) | 7(83.3) | 2(50.0) | 1(50.0) | |||
MSAP | n = 0 | n = 13 | n = 2 | n = 10 | ||
Length of hospital stay, days | – | 28.0 ± 12.4 | 23.0 ± 15.5 | 0.333 | ||
In-hospital mortality,(%) | – | 1(7.6) | 1(50.0) | 1 | ||
AKI, n(%) | – | 1(7.6) | 1(50.0) | 1 | ||
MAP | n = 1 | n = 7 | n = 1 | n = 22 | ||
Length of hospital stay, days | – | 18.0 ± 5.7 | – | 12.2 ± 5.0 | ||
Other | SAP | n = 10 | n = 12 | n = 1 | ||
Laparotomy,(%) | 3(33.3) | 1(8.3%) | 0(0) | |||
Length of hospital stay, days | 47.25 ± 40.49 | 45.69 ± 27.16 | – | |||
In-hospital mortality,(%) | 0(0.0) | 1(8.3%) | 0(0) | |||
AKI, n(%) | 7(70.0) | 6(50.0) | 2(100) | |||
CRRT,n(%) | 2(20.2) | 0 | 0(0.0) | |||
MV,n(%) | 8(80.0) | 9(75.0) | 1(50) | |||
MSAP | n = 0 | n = 17 | n = 0 | n = 0 | ||
Length of hospital stay, days | – | – | – | – | ||
In-hospital mortality,(%) | – | – | – | – | ||
AKI, n(%) | – | – | – | – | ||
MAP | n = 3 | n = 2 | n = 1 | n = 10 | ||
Length of hospital stay, days | 21.3 ± 6.0 | 18.0 ± 5.7 | – | 12.0 ± 5.3 |
Adjusted OR (95%CI) | P adjusted | |
---|---|---|
Antibiotics | ||
In-hospital mortality | 0.154 (0.033–0.713) | < 0.017* |
Laparotomy | 0.017(0.002–0.167) | < 0.001* |
MV | 0.220 (0.039–1.246) | 0.087 |
AKI | 1.528(0.382–2.623E+ 36) | 0.549 |
CRRT | 0.971 (0.000–1.246) | 0.971 |
Adjusted OR (95%CI) | P adjusted | |
---|---|---|
Antibiotics | ||
In-hospital mortality | 0.005 (0.000–0.676) | 0.03* |
Laparotomy | 0.086 (0.015–0.485) | 0.005* |
MV | 0.112 (0.012–1.065) | 0.057 |
Antibiotics | ||
In-hospital mortality | ||
Third generation cephalosporin | 1.286(0.194–8.534) | 0.795 |
Carbapenem | 0.026(0.001–0.581) | 0.021* |
Laparotomy | ||
Third generation cephalosporin | 0.088(0.010–0.803) | 0.031* |
Carbapenem | 0.069(0.010–0.497) | 0.008* |
MV | ||
Third generation cephalosporin | 0.129(0.011–1.154) | 0.103 |
Carbapenem | 0.135(0.013–1.457) | 0.099 |